The present invention relates to a process for preparing Lomitapide or its pharmaceutically acceptable salt thereof having high purity with acceptable levels of impurities.

The present invention relates to a process for preparing Lomitapide or its pharmaceutically acceptable salt thereof having high purity with acceptable levels of impurities.

The present invention relates to a process for preparing Lomitapide or its pharmaceutically acceptable salt thereof having high purity with acceptable levels of impurities.

The invention relates to ester compounds of the general formula (I)

##STR00001##

to a process for preparation thereof and to the use thereof. These ester compounds may contain a mixture of at least two compounds of the general formula (I).

The invention relates to ester compounds of the general formula (I)

##STR00001##

to a process for preparation thereof and to the use thereof. These ester compounds may contain a mixture of at least two compounds of the general formula (I).

The invention includes procedures for stereoselective -acylation of carboxylic acids having a -carbon atom. For example, stereoselective acylation procedures include the following reactions: (I)

##STR00001##

The invention includes procedures for stereoselective -acylation of carboxylic acids having a -carbon atom. For example, stereoselective acylation procedures include the following reactions: (I)

##STR00001##

Provided are: a method for producing fluorenylidene diallylphenols represented by formula (1), the method including a reaction step for reacting fluorenones represented by formula (2) and allylphenols represented by formula (3) in the presence of an acid catalyst, excluding compounds having mercapto groups, the amount of acid catalyst being 0.001-20 mol per mol of compound represented by formula (2); and fluorenylidene diallylphenols represented by formula (4). ##STR00001##

Provided are: a method for producing fluorenylidene diallylphenols represented by formula (1), the method including a reaction step for reacting fluorenones represented by formula (2) and allylphenols represented by formula (3) in the presence of an acid catalyst, excluding compounds having mercapto groups, the amount of acid catalyst being 0.001-20 mol per mol of compound represented by formula (2); and fluorenylidene diallylphenols represented by formula (4). ##STR00001##

The present disclosure provides solid forms, including a salt or co-crystal, of Compound I:

##STR00001##

which exhibits Acetyl-CoA carboxylase (ACC) inhibitory activity and may be useful in treating ACC mediated diseases. Also provided herein are processes or steps for the preparation of a Compound I and intermediates useful for the processes or steps described herein.